603077.SH
和邦生物
SSE · Basic Materials · Chemicals · CN
CNY 2.42
+2.11%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.8B | 7.2B | 8.5B | 8.8B | 13.0B |
| Cost of Revenue | 5.9B | 6.4B | 7.9B | 6.8B | 7.5B |
| Gross Profit | 981.5M | 828.0M | 666.8M | 2.1B | 5.6B |
| Operating Expenses | |||||
| R&D Expense | 16.8M | 17.3M | 30.6M | 47.3M | 67.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 403.4M | 407.8M | 415.4M | 413.4M | 845.0M |
| Selling & Marketing Expense | 95.7M | 91.3M | 79.3M | 59.6M | 52.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 681.7M | 671.4M | 609.5M | 554.1M | 1.1B |
| Cost and Expenses | 6.5B | 7.0B | 8.5B | 7.3B | 8.6B |
| Operating Income (EBIT) | (418.4M) | (602.9M) | (61.8M) | 1.5B | 4.5B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (446.4M) | (630.8M) | (65.7M) | 1.5B | 4.5B |
| Income Tax Expense | 101.5M | 81.8M | 5.1M | 257.3M | 668.3M |
| Bottom Line | |||||
| Net Income | (375.3M) | (536.4M) | 31.5M | 1.3B | 3.8B |
| Earnings from Cont. Ops | (547.9M) | (712.7M) | (70.7M) | 1.3B | 3.8B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (375.3M) | (536.4M) | 31.5M | 1.3B | 3.8B |
| Per Share | |||||
| Basic EPS | (CN¥0.05) | (CN¥0.07) | CN¥0.00 | CN¥0.15 | CN¥0.44 |
| Diluted EPS | (CN¥0.05) | (CN¥0.05) | CN¥0.00 | CN¥0.15 | CN¥0.44 |
| Revenue Per Share | CN¥0.86 | CN¥0.90 | CN¥1.03 | CN¥1.01 | CN¥1.50 |
| Shares | |||||
| Basic Shares Outstanding | 8.0B | 8.0B | 8.3B | 8.7B | 8.7B |
| Diluted Shares Outstanding | 8.0B | 8.0B | 8.3B | 8.7B | 8.7B |
| Profitability Metrics | |||||
| EBITDA | — | 394.6M | 918.6M | 2.5B | 5.4B |
| D&A | — | 997.5M | 980.4M | 989.4M | 915.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026